139 related articles for article (PubMed ID: 20575158)
1. Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.
AIDS Patient Care STDS; 2010 Jun; 24(6):395-6. PubMed ID: 20575158
[No Abstract] [Full Text] [Related]
2. Second complete once-daily single tablet therapy in development.
AIDS Patient Care STDS; 2009 Aug; 23(8):680. PubMed ID: 19694037
[No Abstract] [Full Text] [Related]
3. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
Van Gyseghem E; Pendela M; Baert L; Rosier J; Van 't Klooster G; De Man H; Bouche MP; Schueller L; Van Remoortere P; Wigerinck P; Adams E; Hoogmartens J; Van den Mooter G
Eur J Pharm Biopharm; 2008 Nov; 70(3):853-60. PubMed ID: 18657611
[TBL] [Abstract][Full Text] [Related]
4. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Ripamonti D; Maggiolo F
Curr Opin Investig Drugs; 2008 Aug; 9(8):899-912. PubMed ID: 18666038
[TBL] [Abstract][Full Text] [Related]
5. New once-a-day drugs: Truvada and Epzicom.
Berger DS
Posit Aware; 2004; 15(6):38-9. PubMed ID: 15619773
[No Abstract] [Full Text] [Related]
6. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of action and pharmacokinetics of rilpivirine].
Portilla J; Estrada V
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
[TBL] [Abstract][Full Text] [Related]
8. [Introduction. Rilpivirine].
Podzamczer D
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():1. PubMed ID: 24252526
[No Abstract] [Full Text] [Related]
9. [Improved long-term success. New nucleoside for once daily combinations].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
[No Abstract] [Full Text] [Related]
10. New drugs.
Pozniak A
J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271
[No Abstract] [Full Text] [Related]
11. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
[TBL] [Abstract][Full Text] [Related]
12. Rilpivirine: a step forward in tailored HIV treatment.
Schrijvers R; Desimmie BA; Debyser Z
Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920
[No Abstract] [Full Text] [Related]
13. In brief: Truvada for HIV prevention.
Med Lett Drugs Ther; 2012 Aug; 54(1396):63-4. PubMed ID: 22869292
[No Abstract] [Full Text] [Related]
14. [Conclusions. Position of rilpivirine in the management of infection by the human immunodeficiency virus].
Podzamczer D
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():44. PubMed ID: 24252533
[No Abstract] [Full Text] [Related]
15. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Baert L; van 't Klooster G; Dries W; François M; Wouters A; Basstanie E; Iterbeke K; Stappers F; Stevens P; Schueller L; Van Remoortere P; Kraus G; Wigerinck P; Rosier J
Eur J Pharm Biopharm; 2009 Aug; 72(3):502-8. PubMed ID: 19328850
[TBL] [Abstract][Full Text] [Related]
16. AIDS research. Complexity surrounds HIV prevention advances.
Cohen J
Science; 2011 Jul; 333(6041):393. PubMed ID: 21778370
[No Abstract] [Full Text] [Related]
17. FDA notifications. Complera approved.
AIDS Alert; 2011 Nov; 26(11):130-1. PubMed ID: 22164521
[No Abstract] [Full Text] [Related]
18. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.
Richman DD
Antivir Ther; 2001 Jun; 6(2):83-8. PubMed ID: 11491420
[No Abstract] [Full Text] [Related]
19. Generic Truvada approved.
AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
[No Abstract] [Full Text] [Related]
20. Regulatory issues in the era of highly active antiretroviral therapy.
Murray JS
AIDS; 2000; 14 Suppl 3():S219-25. PubMed ID: 11086865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
